Saturday, December 16 , 2017, 4:03 am | Smoke 54º

 
 
 
 

Sansum Diabetes-UCSB Team Earns Award for Translational Research

Local researchers recognized for their work on artificial pancreas project

The Sansum Diabetes Research Institute is pleased to announce that researchers from Sansum and UCSB were among three awardees out of 128 entrants in the second annual Wyss Institute IEEE EMBS Award for Translational Research, which recognizes projects with potential to make “transformative impact on healthcare safety, quality, effectiveness, accessibility and affordability.”

The Sansum-UCSB submission, “Clinical Translation of MPC for the Artificial Pancreas,” describes the researchers’ ongoing work on a system for automatically controlling blood glucose in people with type 1 diabetes — a collaboration that began in 2006. Presenting on behalf of the Sansum medical team and UCSB Chemical Engineering Department were Dr. Frank Doyle III, Dr. Eyal Dassau and Dr. Howard Zisser.

“This is wonderful recognition for the artificial pancreas work at UCSB and Sansum,” said Dr. Doyle, Mellichamp Professor of Process Control in the UCSB Chemical Engineering Department and adjunct senior investigator at Sansum. “We are well known in the diabetes community, but to be recognized across all of translational biomedical engineering is a tremendous honor.”

“This award was a confirmation that a close relationship between engineering and medicine is the right path forward,” said Dr. Dassau, senior investigator and diabetes team research manager at UCSB and adjunct senior investigator at Sansum. “I think that the Wyss Institute’s vision for biologically inspired, interdisciplinary research is exactly what UCSB and Sansum have been doing for the past six years.”

The ultimate goal of artificial pancreas research is to develop products that make living with diabetes safer and easier, explained Dr. Zisser, director of clinical research and technology at Sansum and adjunct professor of Engineering at UCSB. Current artificial pancreas prototypes consist of an insulin pump and a continuous glucose monitor (CGM) that are both controlled by software run on a third device, such as a laptop computer, tablet or mobile phone.

The prototypes are studied in overnight “closed-loop” trials that depend on volunteer “subjects” with Type 1 diabetes, who get to take a break from diabetes self-management but must have their blood drawn frequently as part of the experimental protocol. In supervising the trials, Dr. Zisser works closely with both participants — some of whom have been volunteering to test new diabetes technologies for over five years — as well as the companies that donate insulin pumps, CGMs and other supplies.

“None of this would be possible without our dedicated subjects and industry partners,” he said.

The success of any artificial pancreas system relies on the software program, or algorithm, that analyzes glucose data from the CGM and tells the pump how much insulin to deliver. The Sansum-UCSB team uses a kind of algorithm called model predictive control (MPC), which is traditionally used in oil refineries and chemical plants. Using MPC for glucose control was first proposed in the mid-1990s by a research team including Dr. Doyle, who maintained his interest in the field when he arrived at UCSB in 2002.

“The power of our approach is to use a very flexible yet sophisticated control platform (model predictive control) and to tailor it to the medical needs and safety considerations of the artificial pancreas,” Dr. Doyle said.

The Sansum-UCSB team presented their work along with five other finalists at the 2012 Conference of the Institute of Electrical and Electronics Engineers Engineering in Medicine & Biology Society in San Diego on Aug. 29. The next day, the researchers received $1,000 for their third-place award.

“It’s nice to receive some appreciation of our contribution to the development of an artificial pancreas and other devices that will help with the daily lives of people with Type 1 diabetes,” said Dr. Dassau. But, he added, “The best acknowledgement is to hear from subjects in trials that they’ve had a vacation — a day not having to worry about their diabetes.”

— Sarah Ettman-Sterner is the director of communications for the Sansum Diabetes Research Institute.

 
  • Ask
  • Vote
  • Investigate
  • Answer

Noozhawk Asks: What’s Your Question?

Welcome to Noozhawk Asks, a new feature in which you ask the questions, you help decide what Noozhawk investigates, and you work with us to find the answers.

Here’s how it works: You share your questions with us in the nearby box. In some cases, we may work with you to find the answers. In others, we may ask you to vote on your top choices to help us narrow the scope. And we’ll be regularly asking you for your feedback on a specific issue or topic.

We also expect to work together with the reader who asked the winning questions to find the answer together. Noozhawk’s objective is to come at questions from a place of curiosity and openness, and we believe a transparent collaboration is the key to achieve it.

The results of our investigation will be published here in this Noozhawk Asks section. Once or twice a month, we plan to do a review of what was asked and answered.

Thanks for asking!

Click here to get started >

Support Noozhawk Today

You are an important ally in our mission to deliver clear, objective, high-quality professional news reporting for Santa Barbara, Goleta and the rest of Santa Barbara County. Join the Hawks Club today to help keep Noozhawk soaring.

We offer four membership levels: $5 a month, $10 a month, $25 a month or $1 a week. Payments can be made through PayPal below, or click here for information on recurring credit-card payments.

Thank you for your vital support.



Daily Noozhawk

Subscribe to Noozhawk's A.M. Report, our free e-Bulletin sent out every day at 4:15 a.m. with Noozhawk's top stories, hand-picked by the editors.

Sign Up Now >